News | May 25, 2010

Balloon Catheter Offers Improved Trackability, Flexibility

May 25, 2010 – A balloon catheter technology with enhanced trackability and a redesigned tip for greater flexibility was recently cleared by the U.S. Food and Drug Administration (FDA) and received European CE mark. The noncompliant (NC) Quantum Apex percutaneous transluminal coronary angioplasty (PTCA) dilatation balloon catheter is being launched in European this week and the United States in June.

The NC Quantum Apex Catheter is a high-performance, post-dilatation balloon catheter developed specifically to address physicians’ needs in optimizing coronary stent deployment. Boston Scientific said it represents the next generation of its balloon catheter technology. It is available in a wide array of balloon diameters from 2 to 5 mm, with balloon lengths ranging from 6 to 30 mm. The monorail catheter platform will be available worldwide and both the monorail and over-the-wire (OTW) catheter platforms will be available in the United States.

The NC Quantum Apex Catheter performed very well, offering a noticeably lower profile, excellent trackability and effective post-dilatation,” said Jean Fajadet, M.D., director of the interventional cardiology, Clinique Pasteur, Toulouse, France. He was the first physician to treat patients with the new balloon catheter. “It features an innovative design and impressive performance that should benefit interventional cardiologists and their patients.”

Bruce Brodie, M.D., interventional cardiologist, Moses Cone Heart and Vascular Center, and chairman, LeBauer Cardiovascular Research Foundation, Greensboro, N.C., served as principal investigator of the POSTIT study. He was one of the first physicians in the United States to use the catheter. “Results from the POSTIT clinical study showed that more than 70 percent of coronary stents are not optimally deployed by a stent delivery balloon alone,” said Brodie. “The use of IVUS (intravascular ultrasound) with an adjunctive post-dilatation balloon makes it twice as likely that a stent will be optimally deployed. The NC Quantum Apex Catheter is a great addition to the available post-dilatation balloons, making it easier for physicians to achieve optimal stent deployment.”

For more information: www.bostonscientific.com

Related Content

Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init